InMed Pharmaceuticals Inc. INM

InMed Pharmaceuticals received a Nasdaq notification for failing to meet minimum shareholders' equity compliance requirements. Nasdaq equity deficiency notice raises delisting risk and can sharply pressure stock price and investor sentiment.

InMed Pharmaceuticals Inc. reported full year fiscal 2026 financial results along with a corporate update. Routine earnings release supplies financial metrics that can moderately sway near-term stock sentiment without signaling major strategic shifts.

InMed Pharmaceuticals and Mentari Therapeutics amended their merger agreement and filed a registration statement on Form S-4. Merger amendment and S-4 filing represent major strategic restructuring that can significantly shift company trajectory and investor outlook.

InMed Pharmaceuticals Inc. (INM) announces merger with Mentari, triggering stock alert and potential shifts in company operations and market position. Merger announcement marks major strategic move likely to significantly alter InMed's trajectory and investor sentiment.

InMed Pharmaceuticals merges with Mentari Migraine backed by $290 million financing, fundamentally reshaping its company strategy and market positioning. Merger with substantial financing and strategy overhaul points to major changes in company trajectory.

InMed Pharmaceuticals merges with Mentari Therapeutics to advance migraine prevention therapies. Merger constitutes major strategic move into migraine prevention space with potential to alter InMed trajectory.

InMed Pharmaceuticals Inc. (INM) advances to public markets via reverse merger as a migraine drug developer. Reverse merger grants InMed direct public market access and capital raising capacity for migraine drug development.

InMed Pharmaceuticals Inc. (INM) reports third quarter fiscal 2026 financial results and provides business update. Quarterly financial results and business updates typically influence short-term stock performance and investor sentiment.

InMed Pharmaceuticals Inc. (INM) received a Nasdaq notification for failing to satisfy the minimum $1.00 bid price requirement, having closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance by achieving a $1.00 or higher closing bid price for 10 consecutive business days. Failure to comply may result in delisting proceedings, though INM can address it via reverse stock split or other measures. Nasdaq minimum bid price deficiency introduces delisting risk, moderately impacting investor sentiment and short-term stock performance.

InMed Pharmaceuticals announces positive data from human brain organoid neuroinflammation models supporting the INM-901 Alzheimer's disease program. Positive preclinical data from advanced brain organoid models advances INM-901 in the high-value Alzheimer's market, likely boosting investor sentiment and strategic positioning.

InMed Pharmaceuticals Inc. (INM) provides update on pharmaceutical development: advancing lead drug candidates toward IND submission and clinical trials. Advancing lead candidates to IND and clinical trials marks a pivotal pipeline milestone with potential to drive significant investor sentiment and stock performance.

InMed Pharmaceuticals provides update on BayMedica operations and strengthens focus on pharmaceutical development pipeline. Strategic shift toward pharmaceutical pipeline from BayMedica operations signals major realignment with high potential to alter trajectory and investor sentiment.

InMed Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal 2026, highlighting key developments in its business operations. The company continues to advance its cannabinoid-based therapies and is focused on expanding its clinical programs. Financial metrics indicate progress, with increased revenues and reduced losses compared to previous periods. InMed also provided updates on its research initiatives and strategic partnerships aimed at enhancing its market position. The financial results and business updates indicate moderate progress in key areas that could influence future performance.

InMed Pharmaceuticals Inc. held its 2025 Annual General and Special Meeting, where key decisions were made regarding corporate governance and strategic initiatives. Shareholders voted on various resolutions, including the election of directors and approval of stock options. The meeting highlighted the company's commitment to advancing its pipeline and enhancing shareholder value. Decisions made during the meeting may influence the company's strategic direction and operational focus.

InMed Pharmaceuticals Inc. has provided an update on its BayMedica commercial business, highlighting advancements in cannabinoid manufacturing and distribution. The company is focusing on expanding its product offerings and enhancing its market presence. InMed aims to leverage its proprietary technology to meet growing demand in the cannabinoid sector, positioning itself for future growth and profitability. The update indicates significant strategic moves and potential market expansion that could alter the company's trajectory.

InMed Pharmaceuticals Inc. has successfully completed pharmacokinetic studies for its Alzheimer's disease candidate, INM-901, in a large animal model. The studies are a crucial step in the development of INM-901, which aims to address the unmet medical needs in Alzheimer's treatment. The results are expected to support further clinical development and regulatory submissions. Successful pharmacokinetic studies are likely to significantly enhance the development trajectory and investor sentiment for INM-901.

InMed Pharmaceuticals Inc. reported its financial results for the first quarter of fiscal 2026, highlighting key developments in its business operations. The company continues to advance its cannabinoid-based therapies and is focused on expanding its clinical pipeline. Financial metrics indicate progress, with increased revenue and reduced losses compared to previous periods. InMed also provided updates on its research initiatives and strategic partnerships aimed at enhancing its market position. The financial results and business updates indicate moderate progress in operations and potential for future growth, but the overall impact on the company's trajectory remains limited.

InMed Pharmaceuticals Inc. has appointed Mr. John Bathery to its Board of Directors, enhancing its leadership team. Bathery brings extensive experience in finance and corporate governance, which is expected to support InMed's strategic initiatives and growth objectives. The appointment of a new board member with relevant experience may positively influence the company's strategic direction and governance.

InMed Pharmaceuticals Inc. has appointed Mr. Neil Klompas to its Board of Directors. Klompas brings extensive experience in the pharmaceutical and biotechnology sectors, which is expected to enhance the company's strategic direction and governance. The appointment of a new board member may influence the company's strategic decisions and governance but is not expected to drastically change its overall trajectory.

InMed Pharmaceuticals Inc. reported a fiscal year 2025 earnings per share (EPS) of ($8.36), an improvement from ($20.14) in the previous year. This indicates a significant reduction in losses, reflecting potential operational improvements and strategic adjustments within the company. The reduction in EPS suggests a moderately noticeable improvement in financial performance, but further context on revenue and operational changes is needed for a clearer impact assessment.

InMed Pharmaceuticals Inc. reported its full-year fiscal 2025 financial results, highlighting key financial metrics and providing a business update. The company outlined its strategic initiatives and progress in product development, emphasizing advancements in its cannabinoid-based therapies. InMed also discussed its financial position and future outlook, indicating plans for continued growth and innovation in the biopharmaceutical sector. Significant strategic initiatives and advancements in product development are likely to impact future performance and investor sentiment.

InMed Pharmaceuticals Inc. announced the presentation of new preclinical data for its drug candidate INM-901 at the Alzheimer's Association International Conference (AAIC) 2025. The study, conducted on a 5xFAD mouse model, showed long-term treatment effects on cognitive function, inflammation, and neuronal health. Key findings included a reduction in inflammatory biomarkers and improvements in behavioral outcomes, suggesting INM-901's potential as a multi-targeted treatment for Alzheimer's disease. The conference will take place from July 27-31, 2025, in Toronto, Canada. The presentation of promising preclinical data for INM-901 could significantly influence InMed's future performance and investor sentiment regarding its Alzheimer's treatment pipeline.

InMed Pharmaceuticals Inc. has closed a $5 million private placement under Nasdaq rules, issuing 1,952,363 common shares at $2.561 each, along with short-term preferred investment options. The offering, managed by H.C. Wainwright & Co., aims to fund pipeline development, support commercial sales of rare cannabinoids, and cover general working capital. The short-term preferred investment options could yield an additional $4.75 million if fully exercised. The securities were offered to accredited investors and are not registered under the Securities Act. InMed also amended existing preferred investment options to reduce their exercise price. The funding will support pipeline development and commercial activities, which could moderately influence financial performance.

InMed Pharmaceuticals Inc. has announced a private placement of $5 million, priced at-the-market under Nasdaq rules. The offering is intended to support the company's ongoing development and operational activities. The placement is expected to enhance InMed's financial position and facilitate its strategic initiatives. The private placement is likely to provide necessary funding for operational activities, impacting financial performance moderately.

InMed Pharmaceuticals Inc. announced preclinical data showing that INM-901 significantly reduces neuroinflammation in ex vivo models related to Alzheimer's disease. The study demonstrated a statistically significant reduction in pro-inflammatory cytokines and the inflammasome marker NLRP3, indicating INM-901's potential as a therapeutic candidate. The results suggest that INM-901's effects on neuroinflammation are independent of amyloid beta or tau pathology, highlighting its promise for treating various neurodegenerative diseases. The company plans to advance INM-901 through further preclinical studies and IND-enabling studies. Significant reduction in neuroinflammation and pro-inflammatory markers positions INM-901 as a promising therapeutic candidate, potentially altering the company's trajectory in Alzheimer's treatment.

InMed Pharmaceuticals Inc. has appointed CBIZ CPAs P.C. as its new auditor following Marcum LLP's resignation due to CBIZ's acquisition of Marcum's attest business. The resignation was not related to any disagreements over financial statements. InMed's special meeting of shareholders failed to achieve quorum, preventing a vote on a proposal to issue additional shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville. The company has amended the SEPA to allow for a temporary suspension of its registration statement during sensitive information disclosures. Yorkville has agreed not to sell shares during any Black Out Period imposed by InMed. The changes in auditor and SEPA amendments may moderately influence InMed's financial operations and shareholder dynamics.

InMed Pharmaceuticals Inc. reported its financial results for Q3 FY2025, revealing a net loss of $2.12 million, up from $1.72 million the previous year. The increase in losses was attributed to higher research and development expenses. The company continues to advance its drug candidates, INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration, with promising preclinical data. BayMedica's revenues increased by 8% to $1.26 million, although gross margins were pressured by competitive pricing. As of March 31, 2025, InMed had $4.68 million in cash and expects to seek additional funding to support its operations. The advancements in drug development and stable revenue growth indicate a moderately noticeable influence on future performance.

InMed Pharmaceuticals Inc. reported its financial results for the second quarter of fiscal 2025, highlighting key metrics and developments in its business operations. The company continues to advance its cannabinoid-based therapies and is focused on expanding its clinical pipeline. Management provided insights into ongoing projects and strategic initiatives aimed at enhancing shareholder value and market presence. The financial results and updates on clinical projects indicate a moderate influence on the company's future performance and market positioning.

InMed Pharmaceuticals Inc. announced the selection of an intravitreal formulation for INM-089, targeting dry age-related macular degeneration (AMD). The formulation demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and safety margin. Preclinical studies showed significant improvements in retinal function and integrity. The company plans to proceed with GLP-enabling studies and pivotal preclinical toxicology studies. Dry AMD affects an estimated 196 million people globally, with a significant unmet medical need for effective treatments. The advancement of INM-089 in treating dry AMD represents a significant strategic move in addressing a major unmet medical need.

InMed Pharmaceuticals Inc. has announced the granting of a patent for novel compounds, which are expected to enhance its product pipeline and strengthen its intellectual property portfolio. This development is part of the company's ongoing efforts to innovate in the pharmaceutical sector, particularly in cannabinoid-based therapies. The patent is anticipated to provide a competitive edge and potentially attract further investment and partnerships. The granting of a patent for novel compounds is likely to significantly impact InMed's future product offerings and market positioning.